seed
Stage
1
Investors
About
SignaCor is a clinical-stage biotech company developing Cardiaza, a first-in-class epigenetic modifying therapy that targets the underlying disease pathology of symptomatic hypertrophic cardiomyopathy (HCM) by modifying DNA methylation to reduce fibrosis, hypertrophy, inflammation, and improve cardiac function.
Explore SignaCor's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.